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Objective. Klinefelter syndrome (KS) has long-term consequences on bone health. However, studies regarding bone status and
metabolism during childhood and adolescence are very rare. Patients. This cross-sectional study involved 40 (mean age: 13.7 ± 3.8
years) KS children and adolescents and 80 age-matched healthy subjects. For both patient and control groups, we evaluated serum
levels of ionised and total calcium, phosphate, total testosterone, luteinising hormone, follicle stimulating hormone, parathyroid
hormone (PTH), 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D, osteocalcin, bone alkaline phosphatase, and urinary
deoxypyridinoline concentrations.We also calculated the z-scores of the phalangeal amplitude-dependent speed of sound (AD-SoS)
and the bone transmission time (BTT). Results. KS children and adolescents showed significantly reduced AD-SoS (𝑝 < 0.005) and
BTT (𝑝 < 0.0005) z-scores compared to the controls. However, KS patients presented significantly higher PTH (𝑝 < 0.0001) and
significantly lower 25(OH)D (𝑝 < 0.0001), osteocalcin (𝑝 < 0.05), and bone alkaline phosphatase levels (𝑝 < 0.005). Interestingly,
thesemetabolic bone disorders were already present in the prepubertal subjects.Conclusions. KS children and adolescents exhibited
impaired bone mineral status and metabolism with higher PTH levels and a significant reduction of 25-OH-D and bone formation
markers. Interestingly, this impairment was already evident in prepubertal KS patients. Follow-ups should be scheduled with KS
patients to investigate and ameliorate bone mineral status and metabolism until the prepubertal ages.
1. Introduction
Klinefelter syndrome (KS) is a common chromosomal disor-
der with a prevalence of 120–153 per 100,000 live-born male
births [1, 2]. KS is commonly characterized by the presence
of one extra X chromosome in a male phenotype resulting
in a 47, XXY karyotype [2, 3]. The major KS finding is
represented by primary hypogonadism due to seminiferous
tubule dysgenesis and androgen deficiency, resulting in a pro-
gressive testicular failure that begins during pubertal devel-
opment. The clinical phenotype includes increased stature,
gynecomastia, small testes, and infertility [4], and the most
frequently associated medical disorders can be categorized as
follows: (1)motor, cognitive, and behavioural dysfunction; (2)
tumours; (3) vascular disease; and (4) endocrine/metabolic
and autoimmune diseases [5].
KS is an underdiagnosed condition; in fact, only 25%
of patients are diagnosed, with only a minority of those
diagnosed before puberty [2, 3, 6], whereas the majority of
patients are identified after puberty onset [5, 6].
Testosterone (T) is an important hormone that plays a
role especially during puberty to achieve bone maturation
and adequate peak bone mass (PBM). In KS metabolic bone
disorders have been reported [7, 8] and low testosterone
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may be responsible for decreased bone mineral density
(BMD) [7], since it is involved in bonemetabolism regulation
directly, through the osteoblast androgen receptor (AR), and
indirectly, through aromatization of androgens to oestrogen
[8].
In fact, spine BMD in the lumbar region increased
significantly after testosterone treatment in KS adults [9]. On
the contrary, low bone mass was also observed in patients
with normal testosterone levels [10]. Some data seem to
demonstrate that theARCAGpolymorphismmay contribute
to a decreased bone mass [11]. In an interesting study,
Aksglaede et al. analysed the muscle/fat ratio and bone
mineral content (BMC) in 6 KS boys receiving androgen and
18 KS untreated participants and observed an unfavourable
muscle/fat ratio with normal lumbar BMD and whole body
BMC in the untreated KS group [12]. Moreover other studies
showed that 25-OH-vitamin D levels are reduced in KS
adults, highlighting that hypovitaminosis D could be more
important than low T levels in inducing low BMD in these
patients [7]. Other data demonstrated that the femoral neck
BMD improvement after ibandronate therapy was inversely
related to 25(OH)D levels [10].
Finally, a recent study showed that KS patients had
lower total volumetric BMD, reduced trabecular density, and
reduced cortical area and thickness at the tibia, compromis-
ing one strength at this site. These data suggest specific bone
characteristics related to this genetic syndrome with picture
similar to postmenopausal osteoporosis [13].
Studies evaluating the bone status andmetabolismof chil-
dren and adolescents are very rare; however, the limited data
available seem to suggest that this unfavourable metabolic
bone profile may be present in childhood as well [12].
Therefore, the purpose of our study was to evaluate bone
mineral status andmetabolism in a cohort of KS children and
adolescents.
2. Subjects and Methods
Forty nonmosaic KS patients (mean age: 11.96 ± 3.97 years)
were recruited consecutively from February 2013 toMay 2015
at Anna Meyer Children’s University Hospital in Florence,
Italy. The cohort contained both children (19 patients, mean
age: 8.55±1.39 years) and adolescents (21 patients, 15.03±1.60
years). None of the patients had ever received sex hormone
therapy.
The study was conducted according to the Declaration
of Helsinki and the European Guidelines on Good Clinical
Practice. Ethical approval was obtained from the Ethics
Committee of our hospital. Written informed consent was
obtained from parents and patients according to age and
ability to consent.
2.1. Case Definition and Study Protocol. We examined both
prenatally diagnosed patients with KS (𝑛 = 15) and patients
diagnosed during childhood and adolescence (𝑛 = 25). In all
patients, chromosomal analysis was performed on peripheral
blood lymphocytes, and karyotypes were established on 30
metaphases for each patient. In the presence of a prenatal
diagnosis, the karyotype was confirmed postnatally. In some
cases, array CGH (44K array platform Agilent oligonu-
cleotides with a resolution of approximately 100 kb) was also
performed. As reported, patients with a mosaic karyotype
were excluded.
We recorded clinical and demographic data at the base-
line visit, including height, weight, body mass index (BMI),
waist circumference (WC), and pubertal staging.
Participants or parents of both the KS patients and
controls filled out a questionnaire reviewed by the medical
staff during the baseline examination which was related to
the pubertal history, the presence or absence of chronic
health problems, current and past medications, vitamin D
and/or calcium intake, familial and personal bone fracture
history and osteoporosis, and physical activity. KS patients
and controls showing already-known bone metabolic dis-
eases, hyper/hypoparathyroidism, malabsorptive disorders,
chronic renal insufficiency, cancer, and drug addiction
(including any medication that could compromise the study
such as topic or systemic glucocorticoids, anticonvulsant
therapy, calcium, vitamin D supplements in the past six
months, sexual steroids, or GnRH analogues) were excluded.
None of the participants had a recent history of travelling to
warmer, sunnier areas prior to and/or during the study.
Physical activity was assessed with a modified activity
score based on the sports/leisure activities (0, <2, or >2
hours per week). Outdoor exposure was quantified through
questions regarding each subject’s average number of daily
outdoor hours and a prospective daily time-activity diary, as
previously described [14].
Calcium and vitamin D intake was assessed using the
semiquantitative validated Food Frequency Questionnaire
[14, 15]. The selection of items was based on the patient’s diet,
frequency of eating, and relative importance of food items,
such as milk and dairy products (including yoghurt, cheese,
and chocolate), eggs,meat, fish, cereals, bread, vegetables, and
fruits. The subjects were also asked about the portion sizes
that were assessed by variously sizedmodels, and each subject
chose the model closest to the portion size that he usually
consumed, according to Mullen et al. [16].
2.2. Vitamin D Status. Serum 25(OH)D levels were stratified
according to the brackets, ≤10, 11–20, 21–30, and >30 ng/mL,
and were defined as severe deficiency, deficiency, insuffi-
ciency, and sufficiency, respectively, according to previously
established guidelines for bone health (in the absence of a
consensus regarding appropriate levels for endocrine and
extraendocrine health) [15, 17].
2.3. Quantitative Ultrasound (QUS) Scans. Bone mineral
status was evaluated with a DBM Sonic 1200 device (IGEA
Bone Profiler, Carpi, Italy).The device was equippedwith two
probes mounted on an electronic calliper. The emitter probe
was positioned on the medial surface, and the receiver probe
was positioned on the lateral side of the measured phalanx
[17].The time interval between emission and reception of the
ultrasound signal was measured and expressed in m/s. Using
this technique, we measured (1) the amplitude-dependent
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speed of sound (AD-SoS, m/s), which is the interval between
the start time of the transmitted signal and the time at which
the signal received reached the predetermined minimum
amplitude value of 2mV for the first time, and (2) the bone
transmission time (BTT, 𝜇s), which is the difference between
the transmission time in the phalanx soft tissue and the bone
and transmission time in the phalanx soft tissue. AD-SoS
and BTT standard deviation scores (SDS) were automatically
generated [17].
The final result is the average AD-SoS and BTT over
four fingers (digits II–V). All of the QUS measurements
were carried out by the same operator on the patients’
nondominant hands. The coefficients of precision, in vivo,
were 0.8% and 1.5% for AD-SoS and BTT, respectively [17].
Low bone mineral status was defined in the presence of
at least one densitometric parameter, such as AS-SoS or BTT
≤ −2.0 z-scores [17].
2.4. Control Group. The data obtained were compared with
an age-, sex-, and body-size-matched healthy subject control
group (80 subjects, mean age: 12.03 ± 4.12 years). For every
patient, we selected two control subjects that matched the
following criteria: age ± 6 months, height ± 2.0 cm, weight
± 2.0 kg, and equivalent pubertal stage. Informed consent
was obtained from all parents of the subjects. This healthy
control group was randomly selected from a population
survey of healthy Caucasian inhabitants in Tuscany with
no endocrine or metabolic diseases; some of these subjects
had been evaluated for noninflammatory musculoskeletal
complaints.
2.5. Study and Laboratory Methods. Height was measured
using a wall-mounted stadiometer, and weight was measured
to the nearest 0.1 kg. The measurements were performed
by the same trained staff members. We calculated BMI as
weight in kilograms divided by height in metres squared
(kg/m2). Waist circumference (WC) was assessed using
inelastic anthropometric tape with a length of 2m and an
accuracy of 1mm. Measurements were taken at the midpoint
between the last rib and the iliac crest. However, height, BMI,
andWCwere normalised for chronological age by converting
to SDS, as previously described [18]. Pubertal staging was
carried out according to Tanner and Whitehouse’s criteria
using an orchidometer [19].
For adolescent patients in the late phase of puberty,
hypogonadism was defined as total testosterone (T) <
10.4 nmol/L, and severe hypogonadism was defined as T <
8 nmol/L [20].
All participants were examined in the morning after an
overnight fast. Blood samples were collected, and serum and
plasma were immediately separated and stored at −20∘C in
multiple vials for future analysis.
Serum levels of total (normal range (NR) = 2.10–
2.50mmol/L) and ionised calcium (NR = 1.10–1.32mmol/L),
phosphate (NR = 1.4–1.7mmol/L for children aged 2–12 years
and 1.1–1.4mmol/L for youth aged 12–16 years), creatinine,
and albumin were measured by a standard autoanalyser
method routinely used for daily practice.
Serum levels of FSH (pubertal NR = 0.7–11.1 IU/L),
LH (pubertal NR = 0.8–7.6 IU/L), E2 (pubertal NR = 9.9–
24.80 pmol/L), total T (pubertal NR = 2.7–17.3 nmol/L),
DHEAS (NR = 80–560𝜇g/dL), intact PTH (NR = 12–
72 pg/mL), and 25(OH)D (NR ≥ 30 ng/mL) were determined
by chemiluminescent immunometric assays using commer-
cial available kits for the IMMULITE 2000 Automated
Analyser (Diagnostic Products Corporation (DPC), Medical
System, Genova, Italy). The intra-assay and interassay coeffi-
cients of variation (CVs) in these hormone assays were all less
than 8% in the full range.
Serum inhibin B was measured by a specific ELISA
(Oxford Bio Innovation, Oxford, UK) with a detection limit
of 20 pg/mL. Intra-assay and interassay CVs were less than
13% and less than 19%, respectively.
Serum 1,25(OH)2D was determined according to a com-
petitive binding protein assay (Nichols Diagnostics, San Juan
Capistrano, CA, USA). The interassay CV was 8%. The
normal range is stated as 19.9–67.0 pg/mL.
A commercially available radioimmunoassay kit was used
to measure serum osteocalcin levels (CIS Diagnostici S.p.A.,
Tronzano Vercellese, Italy).The sensitivity of the method was
0.50 ng/mL.
Urinary deoxypyridinoline concentrations were mea-
sured using high-resolution chromatography in a fluid envi-
ronment (Medical System, Genova, Italy). We expressed
deoxypyridinoline values in nM for mM of nocturnal 12 hr
urinary creatinine. The intra-assay and interassay CVs were
<9.8%.
The serum level of bone-specific alkaline phosphatase
(BSAP) was measured by immunoassay (Metra Biosystems,
Mountain View, CA, USA) with sensitivity of 0.7U/L and a
CV of 3.9–5.8%.
2.6. Statistical Analysis. Statistical analyses were performed
using SPSSX (SPSSX Inc., Chicago, IL, USA). Summaries of
continuous variables are given as mean ± standard deviation
(or median and range, depending on whether the data were
normally distributed or not). To compare differences, we used
Student’s 𝑡-test and Mann-Whitney 𝑈 test depending on the
distribution of the analysed variable.The chi-squared test and
Fisher’s exact test were used to examine associations between
dichotomous variables. Spearman’s (rank) correlation test
was used to determine the correlation coefficients. We used
multiple stepwise regression to determine the variables (age
(years), serum PTH concentration, ionised and total calcium,
phosphate, BSAP, 25(OH)D and 1,25(OH)2D, osteocalcin,
LH, FSH, total testosterone levels, urinary deoxypyridinoline
concentration, quantitative assessment of physical activity
(hours per week), calcium intake (mg/day), and vitamin D
intake (IU/day)) thatmight correlate independentlywithAD-
SoS z-score values. 𝑝 values < 0.05 were considered to be
statistically significant.
3. Results
Demographic, clinical, and laboratory characteristics of KS
patients and healthy controls are summarised in Table 1.
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Table 1: Baseline characteristics of Klinefelter syndrome (KS) patients and controls.
KS Controls p
Subjects, number 40 80 —
Age, yrs 11.96 ± 3.57 12.03 ± 4.12 —
Children 8.55 ± 1.39 8.50 ± 1.63 —
Adolescents 15.03 ± 1.60 15.24 ± 1.76 —
Height, SDS 0.92 ± 0.67 0.94 ± 0.73 —
Children 0.86 ± 0.69 0.85 ± 0.66 —
Adolescents 1.06 ± 0.61 1.12 ± 0.79 —
BMI, SDS 0.56 ± 0.86 0.63 ± 0.93 —
Children 0.45 ± 1.00 0.52 ± 0.86 —
Adolescents 0.67 ± 0.71 0.71 ± 1.01 —
WC, SDS 0.52 ± 0.66 0.58 ± 0.83 —
AD-SoS, z-score −0.55 ± 1.13 0.12 ± 1.23 <0.005
Children −0.28 ± 1.00 0.02 ± 1.05 NS
Adolescents −0.87 ± 1.27 0.21 ± 1.41 <0.005
BTT, z-score −0.74 ± 0.91 0.02 ± 1.05 <0.0005
Children −0.77 ± 0.98 0.13 ± 0.91 <0.005
Adolescents −0.71 ± 0.77 0.06 ± 1.23 <0.05
Calcium intake, mg/day 760 ± 239 805 ± 250 NS
Vitamin D intake 161 ± 43 182 ± 47 NS
Total calcium, mmol/L 2.38 ± 0.06 2.35 ± 0.10 NS
Ionised calcium, mmol/L 1.09 ± 0.05 1.11 ± 0.08 NS
Phosphorus, mmol/L 1.38 ± 0.15 1.34 ± 0.20 NS
PTH, pg/mL 45.80 ± 18.34 27.21 ± 17.82 <0.0001
Children 30.55 ± 6.43 24.89 ± 5.78 <0.005
Adolescents 59.59 ± 14.07 29.97 ± 14.56 <0.0001
BSAP, U/L 95.71 ± 17.60 114.50 ± 35.82 <0.005
Osteocalcin, ng/mL 78.47 ± 38.72 96.37 ± 26.89 <0.05
Urinary deoxypyridinoline, nM/mM creatinine 38.20 ± 23.47 44.78 ± 23.99 NS
25(OH)D, ng/mL 13.64 ± 6.48 25.21 ± 11.42 <0.0001
1,25(OH)2D, pg/mL 59.35 ± 10.45 45.90 ± 14.58 <0.0001
Total testosterone, nmol/L 5.70 ± 5.39 6.24 ± 5.51 —
LH, U/L 4.10 ± 5.34 3.58 ± 4.01 —
FSH, U/L 8.43 ± 18.53 4.05 ± 4.00 <0.05
Inhibin B, pg/mL 90.42 ± 32.02 131.40 ± 25.66 <0.0001
Estradiol, pmol/L 15.34 ± 8.31 11.87 ± 7.27 <0.05
Testicular volume, cc 2.98 ± 1.56 7.82 ± 6.72 <0.0001
BMI: body mass index; WC: waist circumference; 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)2D: 1,25-dihydroxyvitamin D; PTH: parathyroid hormone.
We found no statistically significant differences in height,
weight, BMI, WC, and pubertal staging between KS and
controls (Table 1). History of fractures was not statistically
different betweenKS and controls (12.5% versus 13.7%).These
results were also confirmed considering the prenatally KS
diagnosed subgroup and the KS group diagnosed during
childhood or adolescence. In addition, no significant dif-
ferences were found in the KS group for calcium intake
(children: 802 ± 267mg/day; adolescents: 776 ± 211mg/day)
and dietary vitamin D intake (children: 193 ± 67 IU/day;
adolescents: 171 ± 49) compared to controls (children:
823 ± 291mg/day and 179 ± 49 IU/day; adolescents: 779 ±
221mg/day and 184 ± 54 IU/day; 𝑝 = NS) (Table 1).
Patients with KS showed significant differences regarding
AD-SoS (−0.55 ± 1.13) and BTT z-scores (−0.74 ± 0.91)
compared to the controls (resp., 0.12 ± 1.23 and 0.02 ± 1.05,
𝑝 < 0.005 and 𝑝 < 0.0005; Figures 1(a) and 2(a)). This
same outcome persisted in the BTT z-score when KS patients
were divided into children (−0.77 ± 0.98 versus 0.13 ± 0.91;
𝑝 < 0.005) and adolescents (−0.71 ± 0.77 versus 0.06 ± 1.23;
𝑝 < 0.05) (Figure 2(b)). On the contrary, the AD-SoS z-
scores were significantly different between KS adolescents
and controls (−0.87 ± 1.27 versus 0.21 ± 1.41; 𝑝 < 0.005)
but not between children and controls (−0.28 ± 1.00 versus
−0.02 ± 1.05) (Figure 1(b)).
Overall, 7/40 KS patients (17.5%) had a low bone mineral
status (z-score ≤ −2.0). This incidence was significantly
higher than that observed in the control group (2/80: 2.5%;
𝑝 < 0.0001). In particular, AD-SoS had a ≤ −2.0 z-score
in 4/40 patients (10% versus 1.25% of controls; 𝑝 < 0.0001)
and BTT z-scores ≤ −2.0 in 3/40 patients (7.5% versus 1.25%;
𝑝 < 0.0001), respectively. Of these, 6/7 KS patients showing
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Figure 1: AD-SoS z-scores in KS patients and controls (a) and in KS patients and controls when classified by age group (as children and
adults) with the relative control groups (b). ∗∗𝑝 < 0.005.
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Figure 2: BTT z-scores in KS patients and controls (a) and in KS patients and controls when classified by age group (as children and adults)
with the relative control groups (b). ∗𝑝 < 0.05; ∗∗𝑝 < 0.005; ∗∗∗𝑝 < 0.0005.
AD-SoS and BTT z-score ≤ −2.0 were adolescents, while
in KS children group the incidence was significantly lower
(28.2% versus 5.3%; 𝑝 < 0.0001).
KS patients did not show statistically different ionised
(1.09±0.05 versus 1.11±0.08mmol/L) and total calcium levels
(2.38 ± 0.06 versus 2.35 ± 0.10mmol/L) and phosphate levels
(1.38 ± 0.15mmol/L versus 1.34 ± 0.20mmol/L) compared
with controls. The ionised and total calcium and phosphate
levels did not differ between KS children and adolescents.
Furthermore, evaluating bone formation or resorption
markers, KS showed reduced levels of BSAP (95.71 ± 17.60
versus 114.50±35.82U/L,𝑝 < 0.005) and osteocalcin (78.47±
38.72 versus 96.37 ± 26.89 ng/mL, 𝑝 < 0.05) (Figures 3(a)
and 3(b)), while we could not find any difference regarding
urinary deoxypyridinoline concentrations (Table 1).
The 25-OH-vitamin D levels were significantly lower
(13.64 ± 6.48 versus 25.21 ± 11.42 ng/mL, 𝑝 < 0.0001)
(Figure 3(c)), whereas PTH levels were significantly higher in
KS patients than controls (45.80±18.34 pg/mL versus 26.89±
15.37, 𝑝 < 0.0001) (Figure 3(d)). Furthermore, we discovered
significant difference regarding PTH levels between children
(30.55 ± 6.43 pg/mL) and adolescents (59.59 ± 14.07 pg/mL;
𝑝 < 0.0001) and between KS population and control group
(children: 24.89±5.78 pg/mL, 𝑝 < 0.005; adolescents: 29.97±
14.56 pg/mL,𝑝 < 0.0001) (Figure 3(e)). In addition, therewas
no statistical difference regarding 25(OH)D levels among KS
and control subjects. Moreover, evaluating KS patients and
controls with the same 25(OH)D levels, themean PTH values
(50.03±17.95 versus 30.25±12.21 pg/mL) and the percentage
of hyperparathyroidism (17.5% versus 2.5%, 𝑝 < 0.0001) were
significantly higher in KS children and adolescents.
Performing a seasonal analysis (winter = November
to April), significantly lower 25(OH)D was found in both
periods in KS patients compared to healthy subjects (winter:
8.4±4.25 versus 18.11±7.78,𝑝 < 0.0001; summer: 16.99±4.88
versus 32.66 ± 8.71, 𝑝 < 0.0001).
Furthermore, we highlighted significant differences
regarding 1,25(OH)2D in KS patients (59.35 ± 10.45 pg/mL)
and controls (45.90± 14.58 pg/mL; 𝑝 < 0.0001) (Figure 3(f)).
At the time of puberty, testosterone serum levels were
normal in 10/21 (47.6%) KS adolescents and in the lower
normal range in 11/21 (52.4%), whereas LH and FSH were
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Figure 3: Bone alkaline phosphatase levels (a), osteocalcin serum levels (b), 25-hydroxyvitamin D levels (c), parathyroid hormone levels in
total (d) and classified by age (as children and adolescents) (e), and 1,25-hydroxyvitamin D levels (f) in KS patients and controls. ∗𝑝 < 0.05;
∗∗𝑝 < 0.005; ∗∗∗𝑝 < 0.0005.
in the normal range in 11/21 (52.4%) KS adolescents and
elevated when compared to the normal reference ranges in
10/21 (47.6%) (Table 1). No KS subjects had hypogonadism
during the period of the study. Inhibin B was not different
if compared to controls in all prepubertal KS patients and in
15/21 (71.4%) KS patients, whereas in 6/21 (28.6%) inhibin B
levels were lower than controls. 17𝛽-Estradiol levels were sig-
nificantly different inKS patients and controls (𝑝 < 0.05), and
the ratio between total 17𝛽-estradiol and total testosterone
(E/T ratio) was significantly higher in KS patients than in
healthy controls (data not shown).
A quantitative assessment of physical activity in patients
with KS and controls did not reveal significant differences
between the two groups: 0 hours per week (34% and 28%,
resp.), <2 hours per week (46% and 50%, resp.), and >2 hours
per week (20% and 22%, resp.).
Correlation analysis showed that AD-SoS and BTT z-
scores correlated negatively with PTH (resp., 𝑟 = −0.46,
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𝑝 < 0.005; 𝑟 = −0.48, 𝑝 < 0.005) and with age (𝑟 = −0.62;
𝑝 < 0.0001) and positively with 25(OH)D levels (𝑟 = 0.47,
𝑝 < 0.005). Both BSAP and osteocalcin levels also showed
a significant correlation with total calcium values (resp., 𝑟 =
0.54 and 𝑟 = 0.63; 𝑝 < 0.005). PTH correlated significantly
with ionised calcium (𝑟 = 0.51; 𝑝 < 0.005), age (𝑟 = 0.61,
𝑝 < 0.0001), total calcium (𝑟 = 0.48, 𝑝 = 0.002), phosphorus
(𝑟 = 0.35, 𝑝 = 0.04), magnesium (𝑟 = −0.76, 𝑝 < 0.0001),
LH (𝑟 = 0.66, 𝑝 < 0.0001), FSH (𝑟 = 0.68, 𝑝 < 0.0001), total
testosterone (𝑟 = −0.66, 𝑝 < 0.0001), vitamin D (𝑟 = −0.35,
𝑝 = 0.04), 1,25(OH)2D (𝑟 = 0.37, 𝑝 = 0.02), and osteocalcin
(𝑟 = −0.47, 𝑝 = 0.002).
The multiple regression analysis included age, sex, PTH,
ionised and total calcium levels, phosphate levels, 25(OH)D
and 1,25(OH)2D levels, serum osteocalcin levels, urinary
deoxypyridinoline concentrations, quantitative assessment of
physical activity, calcium intake, and BSAP levels and we
demonstrated that they are all significant predictors of a lower
AD-SoS z-score, PTH levels (𝑝 < 0.001), and 25(OH)D levels
(𝑝 < 0.005).
4. Discussion
Our results revealed that KS patients have an impaired bone
mineral status that begins early in life. In fact, KS children and
adolescents displayed significantly reduced AD-SoS and BTT
z-scores when compared with healthy subjects. This aspect
is particularly concerning since over 17% of KS children and
adolescents had z-scores ≤ −2.0.
KS children and adolescents also showed an impaired
bone metabolism, with significantly reduced 25(OH)D levels
and higher PTH levels compared with controls. Finally, KS
children and adolescents seem to present reduced levels of
bone formationmarkers, such as BPSA and osteocalcin levels.
The aetiopathogenesis of this impaired bone mineral
status in KS patients may be multifactorial, including the
specific bone characteristics related to this genetic syndrome
and environmental factors, that is, poor vitamin D levels,
as reported by previous studies [7, 21]. Particularly, in our
study, KS patients had vitamin D and calcium intake levels
comparable to those of controls, while their 25(OH)D levels
were significantly lower and PTH levels were significantly
higher than controls. These observations confirm data on
KS adults reported by Ferlin et al. [7] and Bojesen et al.
[21], who showed that 25(OH)D levels were significantly
lower compared with controls and associated to significantly
lower lumbar and femoral BMD. Ferlin et al. also showed
higher levels of PTH, while Bojesen, despite important
hypovitaminosis D, did not show a significant increase in
PTH comparing KS patients to controls. In both studies a
reduction of procollagen type 1 N propeptide (P1NP) levels,
a marker of bone apposition, was described, confirming our
data showing a reduction of osteocalcin and bone alkaline
phosphatase levels, which are markers of bone apposition.
In KS adults, testosterone deficiency is reported to be
associated with a significant decrease in BMD; this deficiency
is considered as the major risk factor for premature osteope-
nia and osteoporosis [22–25] and is associated with alterated
body composition [26, 27].
In KS, this relative androgen deficiency begins after
pubertal onset, and since most KS patients show anticipated
puberty [28, 29], it could be reasonable to find decreasing
BMC. Testosterone is fundamental for bone maturation to
reach the PBM at the end of puberty and to keep it during
adult life, regulating male bone metabolism both indirectly
by aromatization to oestrogen and directly on osteoblasts
through the AR, promoting periosteal bone formation [30]
and reducing bone reabsorption [31].
It has also been reported that both serum levels of
testosterone and LH show a significant association with
osteoporosis or fractures [32–34]. Interestingly, LH was
directly related to a positive influence on bone metabolism
in men: LH receptors are present on osteoblasts, and LH
receptor knockout animals showed age-dependent bone loss
[35]. This aspect has been hypothesized in untreated adult
patients affected by central hypogonadism that, despite sim-
ilar hormonal levels of adults with primary hypogonadism,
displayed significantly lower BMD [36]. Furthermore, recent
evidences have highlighted that FSH have profound effects
on bone and influence proinflammatory and proosteoclas-
togenic cytokine expression [37]. In fact, in postmenopausal
women, increased FSH serum concentrations induce mRNA
expression of genes involved in osteoclastic phenotypes and
function, such as receptor activator of NF-𝜅B (Rank), tartrate-
resistant acid phosphatase (Trap), matrix metalloproteinase-
9 (Mmp-9), and Cathepsin K, in a dose-dependent manner,
probably accelerating bone loss [38].
Therefore, all these factors may have a role in reducing
BMD and impairing the bone metabolism in KS patients.
Nevertheless, these data do not explain our finding of an
impaired bone metabolism also in children with KS, who
usually do not have the typical pubertal problems related to
their syndrome.
Interestingly, some data showed a possible role of vitamin
D pathway in KS. In adults, testosterone acts indirectly on the
parathyroid hormone-vitamin D axis, because testosterone
deficiency is related to a reduction in renal 1a-hydroxylase
activity with a subsequent decrease in 1,25-hydroxyvitaminD
concentration, the active form of vitamin D [11]. Moreover, it
has been demonstrated that testosterone inhibits PTHdepen-
dent osteoclast formation through the androgen receptor but
not through the production of intrinsic oestrogen in mouse
bone cell cultures [39].
It is well known that vitamin D is also an important
factor in bone metabolism in prepubertal subjects and that
vitamin D deficiency may play a role in worsening bone
mass. Low vitamin D and high parathyroid hormone (PTH)
levels are frequent findings in KS patients [7, 21], which have
also been confirmed by our results. Furthermore, the same
authors have showed that vitamin D supplementation seems
to be more effective than T replacement therapy alone in
increasing BMD [7]. This study also showed that calcifediol
supplementation was characterized by a very significant
increase of 25(OH)D levels and a significant reduction of
PTH levels, which still remained high. However, this study
did not present a control group.
Our data interestingly seems to suggest that PTH levels
were significantly higher in KS patients than in controls, even
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in absence of severe hypovitaminosis D, suggesting that KS
patients tend to increase PTH levels more than the general
population.
In conclusion, in adults with KS, the hypogonadism, or
the reduced testosterone levels,may represent one of themost
important causes of reduced bone mineral status. However,
possible new causes for this impairment in KS patients may
be related to specificmechanisms of KS, such as an important
hypovitaminosis D and higher PTH levels, aspects that are
also present before the puberty onset. Additional studies are
necessary to evaluate the bone metabolism in prepubertal
KS patients. However, measures to prevent an impaired bone
mineral status, such as ensuring adequate vitamin D intake,
must be implemented early in life in KS patients.
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